[Adjuvant therapy with vinblastine and interferon in metastatic renal carcinoma].
An integrated therapeutic approach was adopted to treat metastatic renal carcinoma, the reason being: 1) to effect a regression of metastasis that could not be attacked surgically either because of its location or extent; 2) to limit micrometastatic diffusion in patients with N+.0.05 mg/kg Vinblastine was used every three weeks in association with alfa-2A-IFN in a dose of 18 X 10(6) U 3 times a week. Included in this study were twelve patients with renal carcinoma subjected to nephrectomy with lymph nodal metastases and with or without remote M+. Without drawing hasty conclusions, this therapy can be said to have a useful role after correct surgical approach.
Cocimano
V
V
Marino
G
G
Brigato
R
R
Cevoli
R
R
Griffa
D
D
D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery / Q000628:therapy; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000601:surgery*; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy; D008207:Lymphatic Metastasis; D009392:Nephrectomy; D011994:Recombinant Proteins; D012186:Retroperitoneal Neoplasms / Q000556:secondary / Q000628:therapy; D014747:Vinblastine / Q000627:therapeutic use*
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014747:Vinblastine
La terapia adiuvante con VBL + IFN nel carcinoma renale metastatico.